304859-16-3

Usage

Physical appearance

White crystalline solid The compound forms a white solid with a crystalline structure.

Pharmaceutical use

Building block/intermediate in drug synthesis It serves as a starting material or intermediate in the production of various drugs and pharmaceuticals.

Chemical class

Pyrrolidine carboxylic acids It belongs to a group of compounds that contain a pyrrolidine ring and a carboxylic acid functional group.

Targeted medical applications

Central nervous system drugs The compound is commonly used in the production of drugs that affect the central nervous system, such as anti-depressants and anti-psychotics.

Additional properties

Antihypertensive and anti-inflammatory The compound has potential blood pressure-lowering and inflammation-reducing properties.

Ongoing research

Exploration of further medical applications Scientists are investigating the potential use of 1-Cyclohexylmethyl-5-oxo-pyrrolidine-3-carboxylic acid in treating other medical conditions.

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 3218-02-8 cyclohexylmethylamine 

Relevant academic research and scientific papers

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives

A novel lead compound, N-{3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl}-1- methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), was identified as a CCR5 antagonist by high-throughput screening using [125I]RANTES and CCR5-expressing CHO cells. The IC50 value of 1 was 1.9 μM. In an effort to improve the binding affinity of 1, a series of 5-oxopyrrolidine-3- carboxamides was synthesized. Introduction of 3,4-dichloro substituents to the central phenyl ring (10i, IC50=0.057 μM; 11b, IC 50=0.050 μM) or replacing the 1-methyl group of the 5-oxopyrrolidine moiety with a 1-benzyl group (12e, IC50=0.038 μM) was found to be effective for improving CCR5 affinity. Compound 10i, 11b, and 12e also inhibited CCR5-using HIV-1 envelope-mediated membrane fusion with IC50 values of 0.44, 0.19, and 0.49 μM, respectively.

CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

A compound of the formula: wherein R1 is a hydrocarbon group, R2 is a hydrocarbon group having 2 or more carbon atoms, where R1 and R2 may in combination form, together with an adjacent nitrogen atom, a ring optionally having a substituent or substituents, R3 is a hydrocarbon group optionally having a substituent or substituents or a heterocyclic group optionally having a substituent or substituents, R4 is a hydrogen atom, a hydrocarbon group, a heterocyclic group and the like, E is a divalent chain hydrocarbon group and the like, G is CO or SO2, J is a nitrogen atom, a methine group and the like, and Q and R are each a divalent chain C1-3 hydrocarbon group and the like, and a salt thereof show a superior CCR5 antagonistic activity and are useful as agents for the prophylaxis or treatment of HIV infection of human peripheral blood mononuclear cells, particularly AIDS.